Nottingham [England], November 22: The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus. Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.
Oregon Health & Science University researchers and partners are developing what could become the first-ever treatment against the debilitating joint pain that can last months or years after becoming infected with the emerging Chikungunya virus.
Washington [US], November 5 (ANI): A study conducted by an international team of researchers with FAPESP's support shows that infection by chikungunya virus can produce even more severe manifestations than the typical symptoms of the disease, such as acute fever, headache, rash, and intense
Washington D.C [USA], Sep 1 (ANI): Some people infected with chikungunya virus develop chronic arthritis that lasts long as the virus or its genetic material persists in the body undetected even after the infection is cured, suggests a study.
Washington D.C. [USA], Aug 30 (ANI): A recent study revealed how the chikungunya virus continues to cause joint pain for months to years after the initial infection.
Washington D.C. [USA], July 28 (ANI): A disease control centre developed an Autocidal Gravid Ovitrap (AGO trap) that attracts and captures female mosquitoes looking for a site to lay eggs. After which researchers reported that AGO traps successfully protected people from infection with chiku